Skip to main content
SpringerLink
Log in

Direct Costs of Schizophrenia in Italian Community Psychiatric Services

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To estimate resource utilisation and direct costs of treatment for patients with schizophrenia in Italian Community Mental Health Centers (CMHCs).

Design: Multicentre, retrospective observational study. CMHCs recruited all patients who attended a follow-up consultation during the period September to December 1998. At enrolment, psychiatrists completed a questionnaire on consumption of resources in the 2 months before recruitment.

Setting: 14 CMHCs.

Perspective: Italian National Health Service (INHS).

Patients: 702 patients with a diagnosis of schizophrenia or other psychotic disorders, defined according to the Diagnostic and Statistical Manual of Mental Disorders-fourth edition. These patients had been followed by the CMHCs for at least 2 years and attended a follow-up consultation either during the period September to December 1998 or on randomly selected days during this period. Patients were classified into seven groups according to their diagnosis.

Results: The mean direct cost of patients with schizophrenia in the 2-month observation period was 2 234 475 Italian lire [L] (1154.01 Euro; EUR); direct costs ranged from L.1 545 818 to L.2 775 658 (EUR798.35 to EUR1433.51) by prognostic group. There was wide variability for prognostic groups in the impact of most cost components on total cost. Admissions accounted for between 11.4 and 56.3% of the total cost, daycare centre days for between 11.3 and 35.5%, home visits for 7.8 to 16.4%, and day-hospital days for 5.4 to 32.8%. Antipsychotics and anxiolytics were the most prescribed drugs and also the most costly.

Conclusion: Despite the limitations of the study related to the short period considered, we believe this study offers some interesting information on the burden of schizophrenia, a disease for which its cost has received limited attention so far in Italy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1

Similar content being viewed by others

References

  1. Rouillon F, Toumi M, Dansette G-Y, et al. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997; 11 (6): 578–94

    Article  PubMed  CAS  Google Scholar 

  2. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171: 502–8

    Article  PubMed  CAS  Google Scholar 

  3. Tabbane K, Joober R, Spadone C, et al. Mortality and cause of death in schizophrenia: review of the literature. Encephale 1993; 19 (1): 23–8

    Google Scholar 

  4. Opler LA, Caton CL, Shrout P, et al. Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis 1994; 182 (3): 174–8

    Article  PubMed  CAS  Google Scholar 

  5. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures: a preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med 1986; 16 (4): 909–28

    Article  PubMed  CAS  Google Scholar 

  6. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5

    Article  Google Scholar 

  7. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17 (3): 475–81

    Article  PubMed  CAS  Google Scholar 

  8. Burns T, Raftery J. Cost of schizophrenia in a randomised trial of home-based treatment. Schizophr Bull 1991; 17: 407–10

    Article  PubMed  CAS  Google Scholar 

  9. Taroni F. DRG/ROD e nuovo sistema di finanziamento degli ospedali. Roma: Il Pensiero Scientifico Editore, 1996

    Google Scholar 

  10. Del Vecchio M. I contratti tra le aziende USL e le aziende ospedaliere. MECOSAN 1998; (25): 85–105

    Google Scholar 

  11. First MB, Frances A, Pincus HA. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Press, 1996

    Google Scholar 

  12. Beratis S, Gabriel J, Hoidas S. Gender differences in the frequency of schizophrenic subtypes in unselected hospitalized patients. Schizophr Res 1997; 23 (3): 239–44

    Article  PubMed  CAS  Google Scholar 

  13. Seltzer J, Conrad C, Cassens G. Neuropsychological profiles in schizophrenia: paranoid versus undifferentiated distinctions. Schizophr Res 1997; 23 (2): 131–8

    Article  PubMed  CAS  Google Scholar 

  14. Cernovsky ZZ, Landmark JA, Merskey H, et al. The relationship of catatonia symptoms to symptoms of schizophrenia. Can J Psychiatry 1998; 43 (10): 1031–5

    PubMed  CAS  Google Scholar 

  15. O’Leary DS, Flaum M, Kesler ML, et al. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12 (1): 4–15

    PubMed  Google Scholar 

  16. Stober G, Syagailo YV, Okladnova O, et al. Functional PAX-6 gene-linked polymorphic region: potential association with paranoid schizophrenia. Biol Psychiatry 1999; 45 (12): 1585–91

    Article  PubMed  CAS  Google Scholar 

  17. Kaiser R, Konneker M, Henneken M, et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with responseto antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000; 5 (4): 418–24

    Article  PubMed  CAS  Google Scholar 

  18. Ohmori T, Ito K, Abekawa T, et al. Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15-year follow up. Eur Arch Psychiatry Clin Neurosci 1999; 249 (2): 73–8

    Article  PubMed  CAS  Google Scholar 

  19. Benazzi F. DSM-III-R schizophreniform disorder with good prognostic features: a six-year follow-up. Can J Psychiatry 1998; 43 (2): 180–2

    PubMed  CAS  Google Scholar 

  20. Italian Directory of Medicines and Manufacturers (L’informatore Farmaceutico). Milan: Oemf, 1997

  21. Scardovi I, Monari P. Metodologia statistica in biologia e medicina. Bologna: Utet, 1991

    Google Scholar 

  22. Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. Health Policy 2000; 51: 1–18

    Article  PubMed  CAS  Google Scholar 

  23. Tediosi F, Parazzini F, Garattini L. Cost of schizophrenia studies: a methodological review. Eur J Health Econ 2000; 1 (1): 14–9

    Article  Google Scholar 

  24. Amaddeo F, Beecham J, Bonizzato P, et al. The use of a case register to evaluate the costs of psychiatric care. Acta Psychiatr Scand 1997; 95: 189–98

    Article  PubMed  CAS  Google Scholar 

  25. Muller CF, Caton CLM. Economic costs of schizophrenia: a post discharge study. Med Care 1983; 21 (1): 92–104

    Article  PubMed  CAS  Google Scholar 

  26. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia — 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30 (5): 196–205

    PubMed  CAS  Google Scholar 

  27. Evers SMAA, Ament AJHA. Costs of schizophrenia in The Netherlands. Schizophr Bull 1995; 21 (1): 141–53

    Article  Google Scholar 

  28. De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998; 24 (4): 519–27

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by a financial contribution from Eli Lilly Italia S.p.A., Lundbeck Italia S.p.A., Janssen-Cilag Italy, Pfizer Italiana S.p.A., Sanofi - Synthelabo S.p.A.

The authors acknowledge useful critical comments from Guido Bertolini. Special thanks go to Judy Baggott and Clara Chiantaretto for editing the manuscript. The opinions expressed and any errors made are, however, the responsibility of the authors alone.

Gruppo di Studio SCORE: Dr G. Blasi, Dr A. Bono, Dr C. Bruno, Dr W. Di Munzio, Dr A. Fiorillo, Prof. P.M. Furlan, Dr. R. Laneri, Dr F. Lombardi, Dr G. Marra, Dr E. Pedrini, Dr E. Pirfo, Dr E. Serio, Prof. M. Viola, Dr A. Virgilio.

We also wish to thank Manuel Negri (data management) and Sonia Cipriani (data analysis) for their assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Centre for Health Economics ‘Angelo e Angela Valenti’ of the ‘M. Negri’ Institute, CESAV, Bergamo, Italy

    Livio Garattini, Carlotta Rossi & Fabrizio Tediosi

  2. Hospital Trust ‘S. Gerardo’ di Monza, Bicocca University of Milan, Psychiatry U.O. 37, Monza, Italy

    Cesare Cornaggia

  3. U.O. 16 Department of Mental Health, Hospital Trust ‘Bolognini’, Seriate, Bergamo, Italy

    Giampiero Covelli

  4. Laboratory of Epidemiology and Social Psychiatry of the ‘M. Negri’ Institute, Milan, Italy

    Corrado Barbui

  5. Laboratory of Epidemiology of the ‘M. Negri’ Institute, Milan, Italy

    Fabio Parazzini

Authors
  1. Livio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlotta Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabrizio Tediosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cesare Cornaggia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giampiero Covelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Corrado Barbui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabio Parazzini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Livio Garattini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garattini, L., Rossi, C., Tediosi, F. et al. Direct Costs of Schizophrenia in Italian Community Psychiatric Services. Pharmacoeconomics 19, 1217–1225 (2001). https://doi.org/10.2165/00019053-200119120-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200119120-00004

Keywords

Search

Navigation